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Background/aim: The members of the inhibitors of apoptosis protein (IAP) family inhibit diverse components of the caspase signaling
pathway, notably caspase 3, 7, and 9. ILP-2 (BIRC-8) is the most recently identified member of the IAPs, mainly interacting with caspase
9. This interaction would eventually lead to death resistance in the case of cancerous cells. Therefore, structural modeling of ILP-2 and
finding applicable inhibitors of its interaction with caspase 9 are a compelling challenge.
Materials and methods: Three main protein modeling approaches along with various model refinement measures were harnessed to
achieve a reliable 3D model, using state-of-the-art software. Thereafter, the selected model was employed to perform virtual screening
of an FDA approved library.
Results: A model built by a combinatorial approach (homology and ab initio approaches) was chosen as the best model. Model refinement
processes successfully bolstered the model quality. Virtual screening of the compound library introduced several high affinity inhibitor
candidates that interact with functional residues of ILP2.
Conclusion: Given the 3D structure of the ILP2 molecule, we found promising inhibitory molecules. In addition to high affinity towards
the ILP2 molecule, these molecules interact with residues that play pivotal rules in ILP2-caspase interaction. These molecules would
inhibit ILP2-caspase interaction and consequently would lead to reactivated cell apoptosis through the caspases pathway.
Key words: BIRC-8, apoptosis, Robetta, modeling

1. Introduction
As a physiological cell death process, apoptosis extensively
regulates development, hemostasis, and immune
responses of the cells. A balance between proapoptotic and
antiapoptotic signals determines the cell’s fate (1). Inhibitors
of apoptosis protein (IAP) family members are one of the
main apoptosis regulators (2). IAP family members inhibit
many types of the caspase signaling pathways, namely
caspase 3, 7, and 9 (3). Human IAPs family proteins are
composed of eight members, including cellular IAP 1
(c-IAP1), cellular IAP 2 (c-IAP2), IAP-like protein 2 (ILP2), melanoma IAP (ML-IAP), X-chromosome-linked IAP
(XIAP), neuronal apoptosis inhibitory protein (NAIP),
BIR repeat-containing ubiquitin conjugating enzyme
(4), and survivin. All members are characterized by the
presence of a BIR domain (5).
* Correspondence: parviz.kokhaei@ki.se

ILP-2 (BIRC-8) is the most recently identified member
of the IAP family, containing a RING finger domain and only
one BIR domain. ILP-2 expression is restricted to humans
and great apes. Various normal tissues such as the testis and
lymphoblastoid tissue express ILP-2. This protein inhibits
cell death through Bax or caspase 9. More interestingly,
instances of increasing expression levels of ILP-2 were
recently reported in breast cancer patients. However, Fas
ligand and tumor necrosis factor-mediated cell death has
not been induced following ILP-2 overexpression (6).
Overexpression of IAP family members is reported
in different types of cancers by inhibition of caspases
and indirect modulation of NF-κB signaling. Targeting
the functions of the IAP family members is an intriguing
strategy to overcome cancer cells that are increasingly
resistant to standard chemo and radiation therapies (7).
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In this regard, modeling of the ILP-2 3-dimensional
(3D) structure as a member of the IAP family would be of
great significance. A 3D structure would be applicable to
find novel inhibitors for ILP2 and caspase 9 interactions.
In the present study, we aimed to find such inhibitors
capable of solving cancer cells resistance to death.
2. Materials and methods
2.1. Sequence retrieval and BLAST search
Protein sequence of ILP-2 was obtained from UniProt
(Universal Protein Resource) knowledgebase at http://
www.uniprot.org/. To perform homology modeling
predictions, the NCBI protein BLAST tool at http://blast.
ncbi.nlm.nih.gov/Blast.cgi was used to arrive at a suitable
template structure. The BLAST plan was restricted for
Homo sapiens only while Protein Data Bank proteins were
set to be the target database; all other parameters were set
as default.
2.2. Protein modelling
Since BLAST search did not find any suitable template for
ILP-2 homology modeling, we used both fold recognition
and initio modeling approaches for model construction.
The I-TASSER server (http://zhanglab.ccmb.med.umich.
edu/I-TASSER/), building its 3D models based on multiplethreading alignments by LOMETS and iterative template
fragment assembly simulations, was employed for the ILP2 structure prediction. According to the CASP7, CASP8,
CASP9, and CASP10 experiments, I-TASSER ranked as
the no. 1 server for accurate protein structure prediction.
The other software employed for ILP-2 3D structure
prediction was Robetta (http://robetta.bakerlab.org/). This
server predicts protein domain structures based on both
ab initio and comparative modeling approaches. Using a
complete automated method, the Rosetta de novo protocol
was used for domains modeling without a detectable PDB
homology study while detecting template PDBs, which
are used to build comparative models by locally installed
versions of HHSEARCH/HHpred, RaptorX, and Sparks-X.
2.3. Model quality assessment
To assess the quality of the obtained files from
the predicted models, PDB files of models were input into
the QMEAN model quality assessment server (http://
swissmodel.expasy.org/qmean/cgi/index.cgi). In order
for the composite scoring function to estimate both global
and local errors on the basis of one single model, QMEAN
could help to determine the best predicted model in
further QMEAN assessment and structure validation. The
Prosa server (https://prosa.services.came.sbg.ac.at/prosa.
php) was used for further structure validation.
2.4. Model refinement and molecular dynamics analyses
As the first step through the model refinement process,
the ModLoop server (http://modbase.compbio.ucsf.edu/
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modloop/) was used to rectify modeling errors on the
selected best model. Loop remodeling was executed on
a loop spanning residues between 150 and 160 residues
of the model that apparently match the QMEAN residue
error plot, indicating a high residue error peak. The result
model was further modified by a full atomic 3D refinement
run employing the server at http://sysbio.rnet.missouri.
edu/3Drefine/. This server modifies protein structures
by a two-step protocol, initialized by optimizing the
hydrogen bonding network and followed by an atomiclevel energy minimization. Finally, to further refine the
model, the CHARMMING server (http://charmming.
org/) was harnessed to conduct a molecular dynamics run
on the refined model. The structure was minimized and
solvated by the CHARMMING server before the main
molecular dynamics run executed. The parameters of the
molecular dynamics run were set to the following: 1000
steps, starting temperature of 210.15, final temperature
of 310.15, temperature increment of 10, steps between
temperature increments of 100, and bath temperature of
310.15.
2.5. Final model validation
To assess the accuracy of prediction, PDB files with PDB
ID of 1XB1 were fed to the Protein Data Bank File Editor
by Jonas Lee to acquire a single BIR Domain of ILP-2.
The identified BIR domains in the predicted model were
superimposed onto equivalent atoms to calculate the root
mean square deviation (RMSD) and the topology score
using the CLICK server (http://mspc.bii.a-star.edu.sg/
minhn/pairwise.html) and the iPBA webserver (http://
www.dsimb.inserm.fr/dsimb_tools/ipba/index.php).
Meanwhile, the TM-align server (http://zhanglab.ccmb.
med.umich.edu/TM-align/) was used to compute the TM
score and RMSD. The stereochemical quality of the final
achieved model was assessed using Procheck software
(http://swissmodel.expasy.org/) to evaluate the geometry
of the residues in the given protein structure. Moreover, the
atomic empirical mean force potential ANOLEA (http://
swissmodel.expasy.org/p) was used to check the packing
quality of the model, performing energy calculations on
the protein chain.
2.6. Compound library preparation and virtual screening
The ZINC12 database (http://zinc.docking.org/),
containing about 35 million compounds for structurebased virtual screening, was used to retrieve a compound
library. The SDF file of a library containing FDA-approved
compounds provided from the DrugBank Database was
downloaded from the available preprepared categories.
PyRx 0.8, available for free download at http://pyrx.
sourceforge.net/downloads, was employed to carry
out docking calculations. PyRx 0.8 uses a large body of
established open-source software such as AutoDock Vina
and AutoDock 4 wizard, AutoDock Tools, Python, and
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Open Babel. AutoDock Vina software is a new program
for molecular docking and virtual screening analysis that
brings about approximately 2 orders of magnitude speedup compared with AutoDock 4. This software significantly
improves the accuracy of the binding mode predictions.
Therefore, we used the Open Babel tool to import the SDF
file of the compound library. Energy minimization runs
and conversion to PBDQT format were executed on all
imported compounds by the Open Babel tool. The ILP-2
model was prepared for docking analysis, adding hydrogen
atoms and merging all nonpolar hydrogen. Calculations
were performed with a grid of 28.54 × 25.15 × 34.38 xyz
points, at grid center of (xyz) –7.05, 14.97, –1.74 to cover
the residues of the BIR domain.
2.7. Compound selection and visual inspection
All compounds with binding energy greater than or
equal to –8 kcal/mol were selected for visual inspection.
The compounds were visually inspected for their spatial
location regarding the caspase 9 interacting amino acids
using 3D structure visualizers like Pymole and Discovery
Studio Visualizer. The structurally important residues for
ILP2 and caspase 9 were assigned using data reported
by Sun et al. (18). The schematic diagram of detailed
protein–ligand interactions were formed using the LigPlus
program.
3. Results
3.1. Sequence and homology analyses
The protein sequence of Baculoviral IAP repeatcontaining 8 (BIRC8) or ILP-2 was retrieved from the
UniProt knowledgebase under the Q96P09 ID code. It is
a cytoplasmic protein comprising 236 amino acids and
containing a BIR domain. Unlike the BLAST search,
results from the PDB Database using this sequence as a
query return similar sequences, the best of which (PDB ID:
1XB1) belongs to the 3D structure of the ILP-2, covering
only 40% of the whole protein length.
3.2. 3D model construction and quality assessment
Full length protein 3D models of ILP-2 were successfully
built by the I-TASSER and Robetta servers. Based on their
scoring algorithms, each server provides 5 top predicted
models. Quality assessment z-scores were calculated for
the best models predicted by both QMEAN and Prosa
servers (Table 1).

3.3. Model refinement and molecular dynamics
Feeding the best predicted model into the loop remodeling
process resulted in resolving the existing high residue
error peak, spanning a region containing 150-10 amino
acids. Loop modeling together with refinement performed
by the 3D refine server improved the quality z-cores for
both QMEAN and Prosa servers (Table 1). Ultimately the
molecular dynamics analyses, performed on the refined
model, formed the final coordinates of the ILP-2 model
(Figure 1).
3.4. Final model validation
RMSD calculations following the superimposition
between the final model and the BIR domain indicate that
the equivalent residues of the predicted model take similar
coordinates to the experimentally resolved structure
(Figure 2). RMSD values were 1.09, 1.26, and 1.26 for
Click, iPBA, and TMalign respectively. Meanwhile, the
TM score and topology score were 0.8 and 1, respectively,
for superimposed structures. The quality score of the
final model was –0.32 for the Procheck total G-factor.
The Ramachandran plot for the finally achieved structure
revealed that more than 90% of residues are in the allowed
regions (Figure 3). ANOLEA results for the finally refined
model indicated that most of the amino acids are in their
favorable energy environment with acceptable QMEAN
scores (Figure 4).
3.5. File preparation and virtual screening
The library of FDA-approved compounds contains 2136
molecules, some of which are different conformations

Table 1. Quality scores for original and refined models.
Quality assessment

QMEAN z-score

Prosa z-score

I TASSER

–4.4

–5.95

Robetta

–2.9

–5.98

Refined model

–2.5

–5.75

Figure 1. The 3D structure of the finally refined model of the
ILP2 is presented. The structure is colored from the N to the C
terminal in blue to red. The BIR domain is colored in green.
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of the same molecule. The energy of all compounds is
minimized and converted to PDBQT format using Open
Babel tool. PDBQT file format for the predicted model
was generated using PyRx. Performed virtual screening
analysis resulted in several predicted conformations of
the docked compound and the macromolecule for each
compound of the library along with their binding energy.

Figure 2. Superimposed structures of the predicted BIR model
with the experimentally resolved structure of the same region.

3.6. Compound selection
Over 2100 compound/protein interactions were predicted
using AutoDock Vina software, among which 67 complexes
got ≤–8 kcal/mol binding energy. All these complexes
were visually inspected and 14 complexes were found to be
in a spatial location suitable to interfere with interactions
of caspase 9-interacting ILP2 amino acids. Among the 14
compounds, all 14 were found to have actual interactions
with caspase 9-interacting ILP2 amino acids. Table 2
lists these compounds and their properties along with a
list of caspase 9-interacting ILP2 amino acids. Figure 5
shows spatial location of the 14 selected compounds in

Figure 3. A Ramachandran plot for the finally achieved model. Only 2 amino acids
(GLU34 and THR 95) are in the disallowed region.
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Figure 4. ANOLEA and QMEAN plots for the finally achieved model.
Negative values represent a favorable energy environment for a given amino
acid, indicating the accuracy of the modelling process. Lower QMEAN values
correspond to regions in the model being potentially more reliable.
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Table 2. Compound and amino acid lists for ILP2 and caspase 9 interaction.
The list of compounds bearing high binding energies (≤–8) and also blocking
the caspase 9 interacting amino acids is presented. Important amino acids
that take part in ILP2 and caspase 9 are listed.
ZINC ID

Binding energy
(kcal/mol)

List of caspase 9-binding
amino acids of ILP2

ZINC00020243

–8.9

A90

ZINC19594557

–8.5

H82

ZINC02568036

–8.4

R85

ZINC52955754

–8.3

E58

ZINC03978005

–8.2

E53

ZINC33359785

–8.2

D54

ZINC95862733

–8.2

R25

ZINC01550477

–8.1

E21

ZINC01612996

–8.1

V18

ZINC01996117

–8.1

Y16

ZINC00057278

–8

M15

ZINC00538275

–8

I9

ZINC28240499

–8

W14

ZINC53073961

–8

Q33

-

-

N48

-

-

W49

-

-

E88

-

-

E71

-

-

G3

-

-

T13

interaction with the BIR domain of ILP 2. The detailed
interaction network of each ligand is depicted in Figure 6.
According to these diagrams each selected compound is
in interaction with the residues, which are important for
ILP2 and caspase 9 interaction.
4. Discussion
Bioinformatics is an evolving field in contemporary
biology, aiming at implementing computers and their
simulations and calculations to solve biological challenges.
Bioinformatics insinuates itself into various fields of
biology, including immunology (8–11), structural biology,
and molecular interaction studies (12). Especially in the
postgenomic era, bioinformatics helps in dealing with
overwhelming amounts of produced data, avoiding ethical
aspects of animal use, reducing the cost of empirical
studies, designing and searching for novel therapeutics,
and presenting novel hypotheses. In the present study
we employed bioinformatics tools to delve into an FDAapproved compound library in search of potential inhibitors
of ILP-2 and caspase 9 interactions. To this end, initially we
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tried to build a full-length ILP-2 model. As the most reliable
modelling approach, homology modelling was considered
to model the ILP-2 molecule. However, there was no
amenable template for full length model development.
Sharing less than 30% identity between query and subject
makes the prediction more likely to fail accurate modeling,
affected by alignment errors (13). Since the best existing
template just covered 40% of the protein and the rest was
without any templates, homology approaches failed to
build a full length ILP-2 model. However, threading and ab
initio protein modelling approaches successfully managed
to build ILP-2 models. The QMEAN z-score is an absolute
quality score that is independent of protein size. Relating
the model’s structural features to experimental structures
of similar size, QMEAN z-score could be used to select
between alternative structures of a modeled protein. Since
the Robetta model gets better z-scores, we decided to
perform the following analyses on this model.
Although the best modeling criteria were contemplated
during the 3D protein modeling, most of the achieved
models are spurious and their coordinates show

KHALILI et al. / Turk J Med Sci

Figure 5. The 3D structure of the finally refined model of the
ILP2 with interacting compounds is presented. The structure is
colored from the N to the C terminal in blue to red. The BIR
domain is colored in green. The important restudies are colored
in yellow.

discrepancies from native protein structure. To arrive
at robust models and bolster their associated errors,
loop remodeling and model refinement seem inevitable.
Molecular dynamics provides an opportunity to simulate
atomic motions for a certain period of time. During the
dynamics run, the positions of the atoms are changed
according to Newton’s laws of motion. All possible
forces involved in atom motions would be exerted by a
force field and finally the model could get more nativelike coordinates (14). After performing all refinement
processes, our results reveal that the finally achieved model
has high quality scores. Assigning over 90% of its residues
in the favored regions of a Ramachandran plot, getting
RMSD in the range of closely homologous proteins values
(<3 Å) between the experimentally resolved protein and
the predicted model, getting a maximum topology score of
1 (which indicates topologically identical structures) (15),
a TM score of >0.5 for the superimposition fold (which
means the structures share the same SCOP/CATH-two
prominent protein structural classification) (16), and
favorable energy environment for most amino acids of
the predicted structure favors the high quality of the final
model. The existence of a high quality region spanning 71–
81 amino acids is due to the algorithm used by the Robetta
server. This region corresponds to the alpha-Helix of the

ILP2 protein, which belongs to the BIR domain according
to the Uniport database; since there are crystallographically
resolved structures for the BIR domain, Robetta uses
homology modelling to model this region. Therefore,
due to the existence of a suitable template to model the
BIR domain, this region is modeled with high quality.
The high quality peak of this region could be rationalized
considering this fact.
Virtual screening of a large compound library against
a target protein is known to be a useful method to select
hits and search for leads from a vast database. Virtual
screening, compared with laboratory experiments, is
more cost effective, time effectual, labor efficient, and
always a sensible option to reduce the initial number of
compounds before using high-throughput screening
methods (17). Using this strategy would pave the way to
find possible agonists and antagonists of target proteins.
The BIR domain of the ILP2 protein is sequentially and
structurally most relevant to the BIR3 domain of the
XIAP protein. Therefore, equivalent residues in the XIAP
BIR3 domain and the ILP2 BIR domain would contribute
in BIR and Caspase 9 interactions. Given these residues,
determined by Sun et al. (18), it would be possible to find
ILP2 inhibiting compounds. To consider a compound
as a potential inhibitor, it should be in suitable spatial
location and contacting with essential residues of the ILP2
and caspase 9 interaction. Meanwhile, the interacting
compounds should have a stable interaction with the ILP2
molecule. Chang et al. (19) defined a threshold of –7.0
kcal/mol that works well to discriminate between putative
specific and nonspecific bindings with HIV protease.
They claim that applying this threshold to data sets may
be useful in filtering out noise in weakly binding
compounds (19). Since this threshold is defined for
AutoDock users, we used a threshold equal to –8.0 kcal/
mol for our results to be more restrictive in compound
selection. Herein, 14 compounds were screened out of an
FDA-approved library, all of which met the main criteria
for a binding energy threshold, spatial location suitability,
and interaction with caspase 9-interacting ILP2 amino
acids. It could be extrapolated that these compounds
would stably occupy the caspase 9 interaction hot spots.
This would spatially inhibit their interaction, while the
caspase 9-interacting ILP2 amino acids are preoccupied
interacting with selected compounds.
ILP-2 protects cells against apoptosis induction by the
Bax protein. Its interaction with caspases 9, especially in
cancerous cells, results in death resistance of tumor cells
(20). As a conserved mechanism of IAP family members,
the BIR domain of the ILP-2 binds to caspases 3 and 9,
and inhibits apoptosis. The IBM interacting groove is
the most conserved surface structure in BIR-2 and BIR-3
domains that interacts with caspase 3 and 7 and caspase 9,
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Figure 6. The interaction diagram of all 14 compounds in interaction with the ILP2 molecule. Each compound and the amino
acids that have interactions with it are depicted.

respectively (21–23). Therefore, the compounds introduced
in Table 2 may efficiently inhibit the caspase interactions
of the ILP-2 or other BIR domain-containing IAP family
members. Due to their high affinity and their interaction
with functionally important residues of the BIR domain,
these compounds could be considered for functional
inhibition of ILP-2 and subsequently increased apoptosis
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and elevated cell susceptibility for current treatments.
Moreover, since these compounds are screened out of an
FDA-approved library, there is less concerns about their
clinical applications.
In conclusion, using an integrative method, a 3D model
of ILP-2 was constructed and used to screen a compound
library. Consequently, exerting restrictive criteria, several

KHALILI et al. / Turk J Med Sci
potential inhibitors of its interaction with caspase 9
were introduced. Finally, the achieved compounds
could efficiently interact with ILP-2 and inhibit ILP-2
functions that may lead to activated cell apoptosis through

caspase pathway. The high homology of the ILP-2 model
(especially the BIR domain) with other members of the
IAP family suggests that these compounds could have the
same inhibitory effect on the other members of the family.
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